There is a lot of disagreement, even within the neuroendocrine tumor (NET) circles, that there are biomarkers that predict outcomes and some that may even predict responses to therapy, explained Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic.
There is a lot of disagreement, even within the neuroendocrine tumor (NET) circles, that there are biomarkers that predict outcomes and some that may even predict responses to therapy, explained Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic.
Transcript
Are there any identified risk factors for developing neuroendocrine tumors?
Interesting question. So, we have studied that in pancreatic neuroendocrine tumors. We used a large dataset at the Mayo Clinic to look at that. We were not able to find anything that predicted NETs. For small bowel NETs, we know from large population studies in Sweden there may be a low famial risk. So, I would say all patients who have a first degree relative—a parent, or a child, or a sibling—with NETs should seek out one of these medical centers that are actually studying familial NETs, including the NIH [National Institutes of Health] and the University of Iowa.
As for other risk factors, we don’t know. They are becoming more common, partly because we’re better at diagnosing them, but also I think because they are becoming more common. We have essentially failed to identify risk factors.
Are there any identified biomarkers that guide treatment protocol?
It’s a hot topic. I would say for most NET patients, biomarkers add little. There is a lot of disagreement, even within the NET circles, that there are biomarkers that predict outcomes and some that may even predict responses to therapy, and there are some that may have diagnostic value. The most commonly used one is chromogranin. It has such severe limitations for most parts that we can’t rely on it for diagnosis and we can’t really rely on it for treatment decisions.
There are other markers, including the marker called pancreostatin, which was discussed at a couple of posters here, that may have some better, more reliable characteristics than chromogranin A. And then there are some novel genomic markers that have been studied and look promising. But, essentially, larger studies are needed. What we need to know is really, we need to do studies that confirm or refute that these markers actually change treatment decisions and eventually change outcomes. If the marker is not going to change the outcomes, I don’t think we should do it.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More